Audia S, Santegoets K, Laarhoven A G, Vidarsson G, Facy O, Ortega-Deballon P, Samson M, Janikashvili N, Saas P, Bonnotte B, Radstake T R
CR INSERM 1098, University of Bourgogne/Franche-Comté, Dijon, France.
Department of Internal Medicine and Clinical Immunology, Competence Centre for Auto-Immune Cytopenia, Dijon, France.
Clin Exp Immunol. 2017 May;188(2):275-282. doi: 10.1111/cei.12935. Epub 2017 Feb 28.
Splenic macrophages play a key role in immune thrombocytopenia (ITP) pathogenesis by clearing opsonized platelets. Fcγ receptors (FcγR) participate in this phenomenon, but their expression on splenic macrophages and their modulation by treatment have scarcely been studied in human ITP. We aimed to compare the phenotype and function of splenic macrophages between six controls and 24 ITP patients and between ITP patients according to the treatments they received prior to splenectomy. CD86, human leucocyte antigen D-related (HLA-DR) and FcγR expression were measured by flow cytometry on splenic macrophages. The major FcγR polymorphisms were determined and splenic macrophage function was assessed by a phagocytosis assay. The expression of the activation markers CD86 and HLA-DR was higher on splenic macrophages during ITP compared to controls. While the expression of FcγR was not different between ITP and controls, the phagocytic function of splenic macrophages was reduced in ITP patients treated with intravenous immunoglobulin (IVIg) within the 2 weeks prior to splenectomy. The FCGR3A (158V/F) polymorphism, known to increase the affinity of FcγRIII to IgG, was over-represented in ITP patients. Thus, these are the first results arguing for the fact that the therapeutic use of IVIg during human chronic ITP does not modulate FcγR expression on splenic macrophages but decreases their phagocytic capabilities.
脾巨噬细胞通过清除调理素化血小板在免疫性血小板减少症(ITP)发病机制中起关键作用。Fcγ受体(FcγR)参与这一现象,但在人类ITP中,它们在脾巨噬细胞上的表达及其受治疗的调节情况鲜有研究。我们旨在比较6名对照者和24名ITP患者之间以及根据脾切除术前接受的治疗分组的ITP患者之间脾巨噬细胞的表型和功能。通过流式细胞术检测脾巨噬细胞上的CD86、人类白细胞抗原D相关分子(HLA-DR)和FcγR表达。确定主要的FcγR多态性,并通过吞噬试验评估脾巨噬细胞功能。与对照相比,ITP期间脾巨噬细胞上激活标志物CD86和HLA-DR的表达更高。虽然ITP患者和对照者之间FcγR的表达没有差异,但在脾切除术前2周内接受静脉注射免疫球蛋白(IVIg)治疗的ITP患者中,脾巨噬细胞的吞噬功能降低。已知可增加FcγRIII对IgG亲和力的FCGR3A(158V/F)多态性在ITP患者中过度表达。因此,这些是首批支持以下事实的结果:在人类慢性ITP期间IVIg的治疗应用不会调节脾巨噬细胞上FcγR的表达,但会降低其吞噬能力。